<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176277</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-7475-01</org_study_id>
    <nct_id>NCT03176277</nct_id>
  </id_info>
  <brief_title>A Study of ONO-7475 in Patients With Acute Leukemias</brief_title>
  <official_title>A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      [Updated]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with&#xD;
      relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic&#xD;
      syndromes and to assess: i) safety and tolerability and ii) preliminary efficacy of the&#xD;
      combination of ONO-7475 and venetoclax in patients with relapsed or refractory acute myeloid&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">February 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature, and severity of (serious) Adverse Events (Part A)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant ophthalmology examinations (Part A)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant electrocardiogram (ECG) (Part A)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response (CR)/complete response with partial hematologic recovery (CRh) rate (Part D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To assess the preliminary efficacy of ONO-7475 + venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature and severity of (serious) Adverse Events (Part D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475 + venetoclax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of Maximum Tolerated Dose (MTD) (Part A)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>As assessed by the incidence, nature, and severity of (serious) Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of recommended pharmacological dose (Part A)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>As assessed by the Plasma inhibitory activity (PIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of recommended Phase 2 dose (Part D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>As assessed by safety, PK and PD data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax) (Part A)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Assessment of the time to reach maximum observed plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax) (Part D)</measure>
    <time_frame>Day 1 of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Assessment of the time to reach maximum observed plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax) (Part A)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1(each cycle is 28 days)</time_frame>
    <description>Assessment of the maximum plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax) (Part D)</measure>
    <time_frame>Day 1 of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Assessment of the maximum plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC) (Part A)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Assessment of the plasma area under the curve (day 1 and 28) of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC) (Part D)</measure>
    <time_frame>Day 1 of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Assessment of the plasma area under the curve (day 1 of Cycle 2) of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2) (Part A)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Assessment of the elimination half life of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2) (Part D)</measure>
    <time_frame>Day 1 of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Assessment of the elimination half life of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ctrough) (Part A)</measure>
    <time_frame>Cycle 1 predose Day 7, Day 15 and Day 28/ 7 days after the last dosing of ONO-7475 at investigator's discretion (PK follow-up) (each cycle is 28 days)</time_frame>
    <description>Assessment of the trough concentration of ONO-7475 in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ctrough) (Part D)</measure>
    <time_frame>Day 7 and Day 15 of Cycle 1 and Day 1 of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Assessment of the trough concentration of ONO-7475 in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax) - Food effect (Part A)</measure>
    <time_frame>Day 57 (Cycle 3 Day 1) (each cycle is 28 days)</time_frame>
    <description>Assessment of the food effect on the maximum plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax) - Food effect (Part A)</measure>
    <time_frame>Day 57 (Cycle 3 Day 1) (each cycle is 28 days)</time_frame>
    <description>Assessment of the food effect on the time to reach maximum observed plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC) - Food effect (Part A)</measure>
    <time_frame>Day 57 (Cycle 3 Day 1) (each cycle is 28 days)</time_frame>
    <description>Assessment of the food effect on the plasma area under the curve of ONO-7475</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2) - Food effect (Part A)</measure>
    <time_frame>Day 57 (Cycle 3 Day 1) (each cycle is 28 days)</time_frame>
    <description>Assessment of the food effect on the elimination half life of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ctrough) - Food effect (Part A)</measure>
    <time_frame>Day 57 (Cycle 3 Day 1) (each cycle is 28 days)</time_frame>
    <description>Assessment of the food effect on the trough concentration of ONO-7475 in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax) - (Part D)</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Assessment of the time to reach maximum observed plasma concentration of venetoclax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax) - (Part D)</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Assessment of the maximum plasma concentration of venetoclax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC) - (Part D)</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Assessment of the plasma area under the curve of venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2) - (Part D)</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Assessment of the elimination half life of venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ctrough) - (Part D)</measure>
    <time_frame>Day 15 of Cycle 1 and on Day 1 of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>Assessment of the trough concentration of venetoclax in the plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of ONO-7475 (Part A and D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessment of the pharmacodynamic activity of ONO-7475 as assessed by a PIA assay (pAxl/pMer inhibition).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) (Part A and D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>CR/CRh (Part D only)/CRi/MLFS/PR for AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion independence rate (Part D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessment by the usage of blood transfusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) (Part A)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Duration in months from CR/CRi/MLFS/PR to disease recurrence for AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) (Part D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Duration in months from CR/CRh to disease recurrence for AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (Part A and D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Duration in months from date of first study treatment to disease recurrence/treatment failure or death for AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response rate (Part D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessment of the number of patients with complete response (CR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response with partial hematologic recovery rate (Part D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessment of the number patients with complete response with partial hematologic recovery (CRh)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (Part A and D)/ Complete Response with partial hematologic recovery without minimal residual disease (MRD) AML (Part D only)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessed by flow cytometry for patients who achieve CR or CRh (Part D only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Part D)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Duration in months from the date of first study treatment to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>ONO-7475 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Successive dose escalation cohorts to determine MTD/OBD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-7475 + venetoclax (Part D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Successive dose escalation of ONO-7475 cohorts + venetoclax</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-7475</intervention_name>
    <description>ONO-7475 tablets</description>
    <arm_group_label>ONO-7475 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-7475 + venetoclax</intervention_name>
    <description>ONO-7475 tablets + venetoclax tablets</description>
    <arm_group_label>ONO-7475 + venetoclax (Part D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged ≥18 years at time of screening.&#xD;
&#xD;
          2. Written informed consent by the patient (or their legal representative) prior to&#xD;
             admission to this study. In addition, any locally required authorization (Health&#xD;
             Insurance Portability and Accountability Act in the US), must be obtained from the&#xD;
             patient prior to performing any protocol-related procedures, including screening&#xD;
             evaluations.&#xD;
&#xD;
          3. Adequate renal and hepatic function defined as:&#xD;
&#xD;
               1. Total bilirubin within 1.5 x upper limit of normal (ULN), except those with&#xD;
                  Gilberts syndrome for whom this must be ≤3 x ULN&#xD;
&#xD;
               2. AST and ALT ≤2.5 x ULN&#xD;
&#xD;
               3. Calculated creatinine clearance ≥45 mL/min&#xD;
&#xD;
               4. Serum albumin ≥2.5 g/dL For any patient with laboratory values outside the ranges&#xD;
                  outlined above that are considered due to the patient's underlying disease (AML&#xD;
                  or MDS), the patient may be enrolled into the study following consultation&#xD;
                  between the Investigator and the Sponsor's Medical Officer, if the patient is&#xD;
                  likely to benefit from receiving ONO-7475 (based on the Investigator's&#xD;
                  assessment).&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 as assessed during&#xD;
             the screening period and then again anytime during the 2-day period immediately&#xD;
             preceding the start of dosing in Parts A and D.&#xD;
&#xD;
          5. Life expectancy of at least 3 months&#xD;
&#xD;
          6. Sexually active female patients of childbearing potential and sexually active male&#xD;
             patients must agree to use an effective method of birth control (e.g., barrier methods&#xD;
             with spermicides, oral or parenteral contraceptives and/or intrauterine devices)&#xD;
             during the entire duration of the study and for 4 months after final administration of&#xD;
             study drug. Note that sterility in female patients must be confirmed in the patients'&#xD;
             medical records and be defined as any of the following: surgical hysterectomy with&#xD;
             bilateral oophorectomy, bilateral tubular ligation, natural menopause with last menses&#xD;
             &gt;1 year ago, radiation-induced oophorectomy with last menses &gt;1 year ago,&#xD;
             chemotherapy-induced menopause with last menses &gt;1 year ago.&#xD;
&#xD;
          7. Diagnosis of AML or MDS according to WHO criteria 2016 (Part A only).&#xD;
&#xD;
          8. Either criterion is met (Part A only):&#xD;
&#xD;
               1. Patients with R/R AML with at least 5% blasts by BM biopsy or aspirate, or at&#xD;
                  least 1% blasts in peripheral blood, not likely to benefit from standard salvage&#xD;
                  chemotherapy&#xD;
&#xD;
               2. Patients with R/R MDS who are either not eligible for (or unlikely to benefit&#xD;
                  from) other forms of therapy, including HSCT, according to the treating&#xD;
                  Physician/Investigator .&#xD;
&#xD;
          9. All patients must have received at least one previous line of therapy (Part A only).&#xD;
&#xD;
         10. Diagnosis of AML according to WHO criteria (2016) (Part D only).&#xD;
&#xD;
         11. Patients with R/R AML who have no standard-of-care options known to provide clinical&#xD;
             benefit in patients with R/R AML (Part D only)&#xD;
&#xD;
               1. Refractory AML: Patients who have not achieved complete remission after two&#xD;
                  cycles of induction chemotherapy (i.e., anthracycline containing regimen), four&#xD;
                  cycles of hypomethylating agents, or two cycles of other AML therapy&#xD;
&#xD;
               2. Relapsed AML: Patients who have ≥5% BM blasts in BM, or reappearance of blasts in&#xD;
                  the peripheral blood not attributable to another cause (e.g., recovery of normal&#xD;
                  cells following chemotherapy-induced aplasia) or (re)appearance of extramedullary&#xD;
                  disease after CR of prior AML therapy.&#xD;
&#xD;
         12. All patients must have measured BM aspirate blast counts at Screening. Where the&#xD;
             aspirate is hypo cellular or inaspirable a biopsy would be considered (Part D only).&#xD;
&#xD;
         13. All patients must have received 1 to 3 (inclusive) prior AML therapies after first&#xD;
             diagnosis of AML (Part D).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with active central nervous system leukemia.&#xD;
&#xD;
          2. QT interval corrected according to Fredericia's formula (QTcF) prolongation defined as&#xD;
             a QTcF interval &gt;470 msec or other significant ECG abnormalities including second&#xD;
             degree (type II) or third degree atrioventricular block or bradycardia (ventricular&#xD;
             rate &lt;50 beats/min).&#xD;
&#xD;
          3. Clinically significant liver disease, including active viral or other hepatitis,&#xD;
             current alcohol abuse, or severe cirrhosis.&#xD;
&#xD;
          4. Human immunodeficiency virus (HIV), active hepatitis B (HBV) or C (HCV) infection.&#xD;
&#xD;
          5. Retinal disease (e.g., retinitis pigmentosa including Mertk mutations), retinal&#xD;
             hemorrhage or any disorder which may inhibit follow up for retinal toxicity.&#xD;
&#xD;
          6. Serious intercurrent medical or psychiatric illness that will prevent participation or&#xD;
             compliance with study procedures, including serious active infection (including&#xD;
             COVID-19).&#xD;
&#xD;
          7. Acute promyelocytic leukemia (the French-American-British M3 classification).&#xD;
&#xD;
          8. Patients not recovered to Grade 1 or stabilized from the effects (excluding alopecia)&#xD;
             of any prior therapy for their malignancies.&#xD;
&#xD;
          9. Concurrent treatment with other investigational drugs.&#xD;
&#xD;
         10. Daily requirement of ≥10 mg/day of prednisone or equivalent dose of other&#xD;
             corticosteroids.&#xD;
&#xD;
         11. Prior HSCT within 12 weeks of the first dose of study treatment or ongoing&#xD;
             immunosuppressive therapy for graft-versus-host disease.&#xD;
&#xD;
         12. Participation in another clinical trial with any investigational drug within 14 days&#xD;
             or with any licensed drug within five half-lives, prior to the first ONO-7475 dosing&#xD;
             (for Part A) or prior to the first venetoclax dosing (for Part D).&#xD;
&#xD;
         13. Prior AML or MDS therapy (non-experimental) within 14 days or 5 half-lives, whichever&#xD;
             is longer, prior to the first dose of ONO-7475 (for Part A) or prior to the first&#xD;
             venetoclax dosing (for Part D) (except those permitted in Section 7.1) and no residual&#xD;
             toxicity from the prior therapy hindering of the ONO-7475 dosing (for Part A) or&#xD;
             ONO-7475 plus venetoclax dosing (for Part D).&#xD;
&#xD;
         14. Prior radiotherapy within 21 days of screening, with the exception of localized&#xD;
             palliative radiotherapy.&#xD;
&#xD;
         15. Patients undergoing current treatments for other cancers.&#xD;
&#xD;
         16. Pregnant or lactating women.&#xD;
&#xD;
         17. Proliferative disease (white blood cell [WBC] counts &gt;30 x 10e9/L) confirmed prior to&#xD;
             the first dose of ONO-7475 (for Part A) or WBC &gt;25 x 10e9/L in Part D.&#xD;
&#xD;
         18. Active malignancy, other than AML (Parts A and D) or MDS (Part A), requiring systemic&#xD;
             therapy except for those patients who have been diagnosed with either prostate or&#xD;
             breast cancer and who have received a stable dose of hormone therapy for a minimum of&#xD;
             6 months prior to entering this study.&#xD;
&#xD;
         19. Known hypersensitivity to venetoclax (Part D only).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ONO Pharma UK Ltd</last_name>
    <role>Study Director</role>
    <affiliation>Drug Development Division</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ONO Pharma UK Ltd</last_name>
    <phone>+44 (0)2074214920</phone>
    <email>ctinfo@ono-uk.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>George Yaghmour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine - Yale Cancer Center</name>
      <address>
        <city>North Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas Prebet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida (UF) - Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jack Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>James Foran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Onyee Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Winship Cancer Institute Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nikolas Papadantonakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jorge Cortes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joseph Maly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dale Bixby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gail Roboz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rupali Bhave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University (OSU)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alice Mims, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Margaret Kasner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina - Hollins Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Praneeth Baratam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Courtney DiNardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paul Shami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Leukemia, Myeloid, Acute</keyword>
  <keyword>MER</keyword>
  <keyword>MERTK</keyword>
  <keyword>TYRO3</keyword>
  <keyword>AXL</keyword>
  <keyword>AML</keyword>
  <keyword>Relapsed/ Refractory AML</keyword>
  <keyword>TAM</keyword>
  <keyword>MDS</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Relapsed/ Refractory MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

